Clinical Study
Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients
Table 1
Clinical characteristics of DLBCL patients (
).
| Characteristics | Liver dysfunction group, n (%) | Normal liver function group, n (%) | value |
| Average age (years) | 56.7 | 55.8 | 0.760 | Age (years) > 60 | 35 (40%) | 140 (51%) | 0.088 | Sex (male) | 56 (64%) | 156 (57%) | 0.195 | IPI score | | | <0.001 | Low | 26 (30%) | 147 (53%) | | Low-intermediate | 17 (20%) | 54 (19%) | | High-intermediate | 20 (23%) | 43 (16%) | | High | 24 (27%) | 32 (12%) | | Ann Arbor stages III-IV | 57 (66%) | 104 (38%) | <0.001 | Number of extranodal sites ≥ 2 | 35 (40%) | 90 (33%) | 0.192 | Lymphomatous hepatic infiltration | 7 (8%) | 9 (3%) | 0.058 | LDH > normal | 60 (69%) | 94 (34%) | <0.001 | Performance status (ECOG) ≥ 2 | 25 (29%) | 27 (10%) | <0.001 | Presence of B symptoms | 33 (38%) | 59 (21%) | 0.002 | HBV-DNA positive | 5 (6%) | 8 (3%) | 0.213 | Hepatitis C virus | 1 (1%) | 4 (1%) | 0.655 | Liver enzyme (median values [range], IU/L) | ALT | 41.0 (10.0–577.0) | 16.5 (1.0–59.0) | <0.001 | AST | 45.0 (7.0–678.0) | 19.0 (9.0–39.0) | <0.001 | γ-GT | 65.5 (1.0–707.0) | 18.0 (1.0–64.0) | <0.001 | ALP | 89.0 (21.0–1013.0) | 69.0 (39.0–122.0) | <0.001 | Serum cytokines (median values [range]) | IL-2R (U/mL) | 1894.5 (232.0–7500.0) | 615.5 (52.1–7500.0) | <0.001 | IL-6 (pg/mL) | 8.9 (2.0–194.0) | 3.6 (2.0–69.1) | <0.001 | IL-8 (pg/mL) | 43.7 (6.6–3533.0) | 54.0 (5.0–2849.0) | 0.207 | IL-10 (pg/mL) | 7.1 (5.0–1000.0) | 5.0 (4.0–1000.0) | <0.001 | TNF-α (pg/mL) | 19.2 (4.0–275.0) | 9.5 (4.0–151.0) | <0.001 | Treatment | | | <0.001 | R-CHOP | 75 (86%) | 265 (96%) | | CHOP | 4 (5%) | 11 (4%) | | Supportive care | 8 (9%) | 0 (0%) | | CR (%) | 70.0 | 85.8 | 0.004 |
|
|